We have recently shown that Neuropeptide S (NPS) can promote arousal and induce anxiolytic-like effects after central administration in rodents. Another study reported a number of natural polymorphisms in the human NPS receptor gene. Some of these polymorphisms were associated with increased risk of asthma and possibly other forms of atopic diseases, but the physiological consequences of the mutations remain unclear. One of the polymorphisms produces an Asn-Ile exchange in the first extracellular loop of the receptor protein, and a C-terminal splice variant of the NPS receptor was found overexpressed in human asthmatic airway tissue. We sought to study the pharmacology of the human receptor variants in comparison with the murine receptor protein. Here, we report that the N107I polymorphism in the human NPS receptor results in a gain-offunction characterized by an increase in agonist potency without changing binding affinity in NPSR Ile 107 . In contrast, the C-terminal splice variant of the human NPS receptor shows a pharmacological profile similar to NPSR Asn 107 . The mouse NPS receptor, which also carries an Ile residue at position 107, displays an intermediate pharmacological profile. Structureactivity relationship studies show that the amino terminus of NPS is critical for receptor activation. The altered pharmacology of the Ile 107 isoform of the human NPS receptor implies a mechanism of enhanced NPS signaling that might have physiological significance for brain function as well as peripheral tissues that express NPS receptors.
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Neuropeptide S (NPS) is the endogenous ligand of an orphan G protein-coupled receptor (GPCR). The NPS receptor (NPSR) belongs to the subfamily of peptide GPCRs and is widely expressed in the brain, with highest levels found in hypothalamus, amygdala, endopiriform nucleus, cortex, subiculum, and nuclei of the thalamic midline. In contrast, the NPS precursor mRNA is found in only a few brain structures (Xu et al., 2004) . Highest levels of NPS precursor expression were detected in a novel nucleus located in between the noradrenergic locus coeruleus and Barrington's nucleus in the pontine area of the rat brain stem. Other brain regions of high NPS precursor expression include the lateral parabrachial nucleus, sensory principle 5 nucleus, and a few scattered neurons in the amygdala and dorsomedial hypothalamic nucleus. In addition, we found high expression of NPS and NPSR mRNA in endocrine tissues, including thyroid, mammary, and salivary glands, but did not observe significant levels in rat lung tissue.
Central administration of NPS promotes behavioral arousal and suppresses all stages of sleep in rodents. Furthermore, NPS was found to produce anxiolytic-like effects in a battery of four different tests that measure behavioral responses of rodents to novelty or stress. NPS was shown to induce transient increases of intracellular Ca 2ϩ , indicating that it might have excitatory effects at the cellular level (Xu et al., 2004) .
Recently, a number of polymorphisms in the human NPS receptor gene were identified and a specific set of these polymorphisms was linked to an increased susceptibility for asthma and potentially other forms of allergy that are characterized by high IgE serum levels in Finnish and Canadian asthma patients (Laitinen et al., 2004) . The study described a number of risk haplotypes and originally termed the receptor "GPRA isoform A" (for G protein-coupled receptor associ-ated with asthma; GenBank accession number NP_997055; the protein has also been termed GPR 154). This receptor protein is identical to the NPS receptor that we have studied extensively for its pharmacology, distribution, and function in brain (Xu et al., 2004) . One of the single-nucleotide polymorphisms changes the primary structure of the NPS receptor protein to code for an Asn-Ile exchange at position 107 of the mature protein (SNP591694 AϾT; refSNP ID: rs324981; Fig. 1 ). The study also found that a C-terminal splice variant of the receptor, originally termed "GPRA isoform B" (GenBank accession number NP_997056; Fig. 1 ), was overexpressed in human asthmatic airway tissue and that the orthologous murine receptor mRNA was up-regulated in a mouse model of chronic airway inflammation. Immunostaining showed that human bronchial smooth muscle cells express the receptor protein, indicating a potential role in bronchial constriction. These data suggest a possible involvement of the C-terminal splice variant of the NPS receptor in the pathophysiology of asthma, but the report did not describe a functional role for the receptor or its isoforms due to the lack of a pharmacologically useable agonist (Laitinen et al., 2004) . Because of technical constraints, the study also did not distinguish between the Asn 107 and Ile 107 isoforms. In this study, we report the pharmacological characteristics of all three human NPS receptor variants and compare them to the murine NPS receptor. The primary structure of NPSR Asn 107 is identical to isoform A of GPRA. The receptor variant containing isoleucine at position 107 will be referred to as NPSR Ile 107 , and the splice variant containing an alternative C-terminal exon is termed "NPSR C-alt" throughout this article. In this study, we demonstrate that a gainof-function mutation in human NPSR Ile 107 could have physiological significance in tissues or body functions that involve NPS signaling.
Materials and Methods
Cloning and Functional Expression of NPSR Isoforms. Human NPSR Asn 107 cDNA was cloned as described previously (Xu et al., 2004) . The Ile 107 isoform of NPSR was generated by PCR using synthetic oligonucleotides and the QuikChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The C-terminal splice variant of NPSR (NPSR C-alt) was generated by recombinant PCR. First, the alternatively spliced exon was cloned by PCR from human genomic DNA using primers NPSRB5 (5Ј-ATCTCTTTCCCCTG-CAGGGTCATCCGTCTCC-3Ј) and NPSRB3-XbaI (5Ј-TTTCTA-GAGAGCTGTCACCTTGGAA-3Ј, XbaI site underlined). Recombinant PCR was carried out with the cloned exon and human NPSR Asn 107 cDNA as templates using primers NPSRA5-XhoI (5Ј-ATACTCGAGCCATGCCAGCCAACTTCACAGAGGGCA-3Ј, XhoI site underlined) and NPSRB3-XbaI. The products were digested, gel-purified, and cloned into pcDNA3.1-hygromycin (Invitrogen, Carlsbad, CA). Mouse NPSR was cloned by nested PCR from mouse total brain cDNA (BD Biosciences Clontech, Palo Alto, CA). Firstround primers were 5Ј-GCTGCAGGTGCAGAGACAGTGAG-3Ј and 5Ј-GAGAGCTGACTAAGTTCAGCC-3Ј. PCR products were further amplified using primers 5Ј-TTGGATCCCTGCCTGAGCCAT-GCCA-3Ј (BamHI site underlined) and 5Ј-TTTCTAGATCAGGGTT- TAGATGAATTC-3Ј (XbaI site underlined). The products were digested with the respective restriction enzymes and cloned into pcDNA 3.1-hygromycin. Transfection of CHO and HEK293 cells was carried out using Lipofectamine (Invitrogen) as described previously (Xu et al., 2004) . Selection of stable clones was achieved by culturing transfected cells in medium containing 400 mg/l hygromycin (Omega Scientific, Tarzana, CA). For transient expression, transfected cells were cultured for 72 h without antibiotic selection.
Detection of Endogenous NPSR Expression in Cell Lines. Total RNA from a number of human cell lines (HEK293, U373 MG, 1321N, Caco-2, LoVo, DLD-1, Colo205, HCT116, HT-29, SW480, and SW1116) was extracted and converted into single-strand cDNA using reverse transcriptase (New England Biolabs, Beverly, MA) and oligo(dT) primers. Quantitative real-time PCR was carried out as described using primers specific for human NPSR (Xu et al., 2004) .
Measurement of Intracellular Ca 2؉ Mobilization. Changes of agonist-induced intracellular Ca 2ϩ were measured using the fluorimetric imaging plate reader technology as described previously (Reinscheid et al., 2003; Xu et al., 2004) . NPS and truncated NPS peptides were a gift from Phoenix Pharmaceuticals (Belmont, CA). Dose-response curves were calculated using Prism (GraphPad Software Inc., San Diego, CA). Mean EC 50 values of populations of stable clones expressing individual NPSR variants were compared using unpaired Student's t test, and p Ͻ 0.05 was considered significant.
Measurement of cAMP Accumulation. cAMP was measured as described previously (Reinscheid et al., 1996) . In brief, stably transfected cells were seeded into 24-well plates and cultured for 24 h. Culture medium was aspirated and exchanged for 200 l of Opti-MEM (Invitrogen) containing 100 M 3-isobutyl-1-methylxanthine and agonists at various concentrations. After incubation for 15 min at 37°C, cells were lysed by adding ethanol to a final concentration of 66%. Aliquots of the lysate were lyophilized, and cAMP content was measured in a radioimmunoassay [either Flashplate; PerkinElmer Life and Analytical Sciences (Boston, MA), or SPA Biotrak; GE Healthcare, Little Chalfont, Buckinghamshire, UK]. Dose response curves were calculated using Prism.
CRE-Luciferase Reporter Gene Assays. HEK293 cells were stably transfected with a reporter gene containing six copies of a cAMP-response element (CRE; sequence CCAAT) in front of a luciferase reporter gene (Promega, Madison, WI) cloned into pcDNA3.1-neomycin (Himmler et al., 1993) . One stable clone showing robust induction of reporter gene expression after forskolin challenge was chosen for further experiments. The different NPSR isoform cDNAs (cloned into pcDNA3.1-hygromycin) were transfected into these cells using Lipofectamine, and stable clones were selected. The same cells and procedures were also used for transient transfection. For induction of reporter gene expression, cells were plated in 96-well plates and incubated with agonist for 5 h in serum-free medium followed by aspiration of the medium and cell lysis with 25 mM Tris phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-N,N,NЈ,NЈ-tetraacetic acid, 10% glycerol, and 1% Triton X-100. After one freeze-thaw cycle, aliquots of supernatant were transferred to white clear-bottom 96-well plates (Greiner Bio-One, Longwood, FL), and luciferase content was quantified by bioluminescence (LucScreen; Applied Biosystems, Foster City, CA). Plates were counted in a scintillation counter using bioluminescence settings (MicroBeta; PerkinElmer Wallac, Gaithersburg, MD).
Cell Proliferation Assays. Cells were seeded in 24-well plates and grown overnight to 60 to 70% confluency. After 24 h of serum starvation, 2 Ci of [methyl-3 H]thymidine was added together with increasing concentrations of NPS. 500 nM prostaglandin E 2 (PGE 2 ) served as a positive control. After a 3-h incubation, cells were washed three times with phosphate-buffered saline and then lysed with 0.5 N NaOH. The lysate was neutralized with 0.5 N HCl, and aliquots were counted in a liquid scintillation counter for incorporated radioactivity.
MAPK Phosphorylation. Agonist-induced phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) was determined as described previously (Saito et al., 2001) . In brief, cells were cultured in 24-well plates in serum-free cell culture medium for 24 h. After stimulation for 5 min at 37°C with increasing concentrations of NPS, cells were washed with phosphate-buffered saline and lysed with 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1.5% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 0.5 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin, and 100 g/ml bacitracin. Lysates were centrifuged, and aliquots of supernatant were electrophoresed on 4 to 10% SDS-polyacrylamide gels. Phosphorylated p42/p44 MAPK was assayed by Western blot. After transfer to Hybond C membranes (GE Healthcare), blots were incubated with anti-phospho-p42/p44 MAPK antibody (dilution 1:1500; Cell Signaling Technology Inc., Beverly, MA) in Tris-buffered saline, 1% nonfat dried milk, 0.2% Tween 20 at 4°C overnight. Horseradish peroxidase-conjugated goat anti-rabbit IgG (dilution 1:2000; Jackson ImmunoResearch Laboratories Inc., West Grove, PA) was used as a secondary antibody. Immunoblots were developed using an enhanced chemiluminescence detection kit (GE Healthcare), and films were scanned by densitometry (UN-SCAN-IT; Silk Scientific Inc., Orem, UT) for quantitative analysis.
Radioligand Binding. Saturation binding experiments in intact cells were carried out exactly as described previously (Xu et al., 2004 Fig. 3 , the mean EC 50 for NPS-induced mobilization of intracellular Ca 2ϩ at NPSR Asn 107 was found to be 13.02 Ϯ 1.18 nM (n ϭ 16 individual stable clones). In contrast, NPSR Ile 107 displayed a more than 10-fold lower mean EC 50 of 1.01 Ϯ 0.13 nM (n ϭ 21). In the clones expressing NPSR C-alt, the peptide showed a mean EC 50 of 32.5 Ϯ 1.15 nM (n ϭ 14). These data demonstrate that NPSR Ile 107 is activated by significantly lower concentrations of agonist than NPSR Asn 107 or NPSR C-alt (F 2,51 ϭ 79.65; p Ͻ 0.0001).
Using the same approach as described before, we compared the EC 50 values of a large number of stable clones established in HEK cells that coexpress the CRE-luciferase reporter gene. As shown in Fig. 3 , HEK cells stably expressing both NPSR Asn 107 and the reporter gene displayed a mean EC 50 of 45.08 Ϯ 1.19 nM for NPS-induced reporter gene expression (n ϭ 7 individual clones). In contrast, cells coexpressing NPSR Ile 107 and the reporter gene showed a mean EC 50 of 0.63 Ϯ 0.43 nM for NPS (n ϭ 21). Cells expressing NPSR C-alt displayed a mean EC 50 of 28.8 Ϯ 1.42 nM in the reporter gene assay (n ϭ 12). Again, these data indicate that NPSR Ile 107 is activated at significantly lower agonist concentrations than NPSR Asn 107 or the alternatively spliced NPS receptor (F 2,37 ϭ 67.31; p ϭ 0.0001). Taken together, these data indicate that the Ile 107 mutation produces a gainof-function in the NPS receptor protein, whereas the alternatively spliced C terminus does not appear to affect agonist potency.
Many GPCRs have been shown to affect cell growth that might have significance in malignant or other pathological processes. To investigate whether NPSR can affect cell proliferation at natural levels of receptor expression, we screened a number of cancer cell lines for endogenous NPSR mRNA expression by reverse transcription-PCR. The human colon cancer line Colo205 was found to express NPSR transcripts but did not display agonist-induced second messenger responses (data not shown). However, NPS produced a dosedependent stimulation of thymidine incorporation in Colo205 cells, indicating that the peptide can stimulate cell proliferation and mitogenic signals in these cells (Fig. 4A) . Doses of 0.1 to 10 nM NPS produced maximal thymidine incorporation, exceeding the effect of the well characterized mitogen , or NPSR C-alt cDNA constructs. Bioluminescence was determined from triplicate incubations repeated at least twice, and data are presented as means Ϯ S.E.M. 
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PGE 2 on these cells. The human colon cancer cell line DLD-1, which does not express NPSR transcripts, served as a negative control and showed no NPS-dependent thymidine incorporation (data not shown). We next examined potential intracellular mediators of the proliferative response elicited by NPS. The p42/p44 MAPK is a well known integrator of mitogenic signals, and many GPCRs have been shown to increase phosphorylation of MAPK upon agonist stimulation. , were chosen to examine the structure-activity relationships of various NPS fragments. These NPS fragments represent potential processing products that could result from proteolytic cleavage of human NPS 1-20. In addition, we also tested the effect of rat and mouse NPS 1-20 on these cells. As shown in Fig. 5 , A and B, and Table 1 , most carboxyl-terminally truncated fragments of NPS retained full agonist potency at both NPSR isoforms. Rat and mouse NPS 1-20 seem to be slightly more potent agonists at both NPSR isoforms compared with the human peptide. Interestingly, NPS 1-12 shows greatly decreased agonist activity at NPSR Asn 107 while still behaving as a full but weakly potent agonist at NPSR Ile 107 . Further deletion of the two lysine residues at positions 11 and 12 produced NPS 1-10. NPS 1-10 displayed full agonist activity at both NPSR isoforms, albeit with significantly higher potency at NPSR Ile 107 . Deletion of the three amino-terminal amino acids (NPS 4 -20) completely abolished agonist activity. These data indicate that the N terminus of NPS contains the pharmacophore. The two lysine residues at positions 11 and 12 seem to attenuate activation of the receptor when exposed at the C terminus, because further C-terminal deletion to NPS 1-10 restored agonist activity. Because of the peculiar pharmacology of NPS 1-12, this fragment was also tested for possible antagonist activity but failed to block activation of the two human receptor isoforms by NPS 1-20 (data not shown). Overall, the various NPS fragments displayed a 5 to 10-fold clones: 12.5 Ϯ 3.5 fmol/10 5 cells; average B max of NPSR Asn 107 clones: 3.9 Ϯ 1.5 fmol/10 5 cells; n ϭ 4 for each receptor variant). Overall, the levels of NPS receptor expression are low compared with other GPCRs expressed in the same cellular environment. Dose-response relationship experiments for Ca 2ϩ mobilization, cAMP formation, and MAPK phosphorylation were performed with individual clones that display very similar receptor levels to correct for possible confounds caused by varying numbers of functional receptors (Figs. 2A, 2B , and 4B). Taken together, our data indicate that the increased potency of NPS at NPSR Ile 107 is not caused by a change in receptor affinity but might reflect an increased intrinsic efficacy of the receptor protein to couple to G proteins and thus to the various second messenger pathways, as described above.
We also investigated the pharmacological profile of the mouse NPS receptor since much in vivo studies on the physiological functions of NPS have been performed in this species (Xu et al., 2004) and increased expression of NPSR has been reported in a murine model of allergic airway inflammation (Laitinen et al., 2004) . The mouse NPSR carries an Ile residue at amino acid position 107, and currently available genetic data do not indicate polymorphic variants at this site in the mouse genome. As shown in Fig. 5C and Table 1 , HEK cells stably expressing mouse NPSR responded to stimulation with various NPS peptides by increasing intracellular free Ca 2ϩ . The EC 50 values and rank order of potency of the various NPS peptides for mobilizing Ca 2ϩ were found to lie in between those obtained with cells expressing human NPSR Asn 107 and NPSR Ile 107 , respectively. Mouse and rat NPS appear to be slightly more potent at mouse NPSR. In contrast to the human NPSR isoforms, the rank order of potency for NPS 1-12 and NPS 1-10 was reversed, indicating that the two carboxyl-terminal lysine residues in NPS 1-12 might interact differently with mouse NPSR than with the human receptors. When analyzing a population of individual HEK clones stably expressing mouse NPSR, we obtained a mean EC 50 value of 4.58 Ϯ 1.28 nM (n ϭ 15 individual clones; Fig. 3 ). Statistical analysis indicated that the mean EC 50 of mouse NPSR was significantly different from both human NPSR Asn 107 (p Ͻ 0.05) and human NPSR Ile 107 (p Ͻ 0.05). Radioligand binding experiments showed that mouse NPSR binds NPS with approximately the same affinity compared with the human NPS receptor variants (Fig. 6) . Note that the IC 50 values for half-maximal displacement of the radioligand in stable HEK cells are ϳ10-fold higher than in CHO cells (IC 50 [CHO] ϭ 0.4 nM; IC 50 [HEK] ϭ 4 nM) that we reported previously (Xu et al., 2004) .
Discussion
In the present study, we have investigated the pharmacological properties and signal transduction pathways of three natural variants of the human NPS receptor and the orthologous mouse protein. We also sought to determine whether the coding polymorphism or alternative splicing of human NPSR would affect the receptor pharmacology in a way that might have functional significance for the pathophysiology of asthma, since the human NPS receptor was recently identified as an asthma susceptibility gene (Laitinen et al., 2004) .
Our data provide evidence for an increased agonist potency at human NPSR Ile 107 . Surprisingly, the N107I point mutation does not affect ligand binding affinity, even though this amino acid is expected to be close to the ligand binding pocket of the receptor protein (Fig. 1) . The endogenous agonist NPS 107 expression is also facilitated in vivo or whether our observation is due to the overexpression system used in our studies. Together, our data indicate that the N107I polymorphism in human NPSR produces a gain-offunction that could have significant functional consequences in physiological processes that involve NPS signaling.
The C-terminal splice variant of NPSR (NPSR C-alt, GPRA isoform B) was described to be significantly overexpressed in airway smooth muscle cells from asthmatic patients compared with healthy controls when studied by immunohistochemical staining (Laitinen et al., 2004) . Our data provide no evidence for an altered second messenger response elicited by NPSR C-alt compared with NPSR Asn 107 . Both receptor variants contain an Asn residue at position 107. It remains to be determined whether the alternative C-terminal tail of the receptor protein can affect other signaling pathways or receptor desensitization and thus have functional significance. Interestingly, the alternative exon giving rise to NPSR C-alt in human is absent from the mouse and rat genome.
Our data show that NPSR can couple to intracellular Ca 2ϩ as well as cAMP pathways, indicating interaction with both G q and G s types of G proteins. The pharmacophore of NPS is contained within the N-terminal part of the peptide, and we describe NPS 1-10 as a minimally active structure. All NPS fragments used in our studies could be produced by proteolytic processing involving trypsin-like cleavage at basic amino acid residues. Some of these fragments retain potent agonist activity. Therefore, it will be important to determine the enzymatic steps involved in the inactivation of this neuropeptide in vivo. Apparently, the NPSR protein cannot be studied easily in transient transfection systems that made the pharmacological analysis of the receptor variants more tedious. One common problem of using stable clones for second messenger assays is caused by the fact that each clone displays an individual pharmacology, and a comparison of too few stable clones can lead to inaccurate assumptions regarding general pharmacological properties. Therefore, we chose to analyze a large population of stable clones and determined mean EC 50 values followed by statistical analysis. This procedure allowed us to detect significant differences in agonistinduced second messenger coupling among the NPSR Asn 107 , NPSR Ile 107 , and NPSR C-alt isoforms, respectively. At present, the functional involvement of NPSR in airway smooth muscle contraction still remains to be verified. According to the report by Laitinen et al. (2004) , the receptor protein seems to be expressed in airway smooth muscle cells that might contribute to bronchial constriction. Our data indicate that activation of NPSR produces an increase in intracellular free Ca 2ϩ and that the NPSR Ile 107 variant, if expressed in airway smooth muscle cells, could thus transmit an enhanced contractile response requiring lower agonist concentrations. Because increased bronchial constriction is one of the physiological hallmarks of asthma (Bousquet et al., 2000) , the gain-of-function mutation in NPSR Ile 107 could therefore be associated with this phenotype. Also, our studies provide evidence for a proliferative effect of NPS using a cellular model of endogenous NPSR expression and demonstrating enhanced phosphorylation of MAPK. Tissue remodeling in asthmatic airways involves proliferation of smooth muscle cells and thickening of basal membranes (Bousquet et al., 2000) . It remains to be determined whether these pathological changes are influenced by NPS receptors endogenously expressed in airway smooth muscle cells. Therefore, further investigations into the functional role of NPSR in airway tissue will be necessary to determine whether the gain-of-function polymorphism in NPSR Ile 107 that we describe in this paper might be involved in any of the pathological events underlying asthma. Ultimately, the development of NPS antagonists will be a critical step to fully understand the physiological functions of NPS signaling.
Naturally occurring polymorphisms that affect receptor function have been identified in numerous GPCRs. Not surprisingly, most of these mutations lead to inactive receptor proteins. The few examples of gain-of-function mutations can be divided into two classes based on their pharmacological phenotype. One group of mutations produces constitutively active receptors that promote second messenger signaling in the absence of endogenous agonist. This type of activating mutations has been found in the glycoprotein-hormone receptor subfamily (luteinizing hormone and thyroid-stimulating hormone receptor), parathyroid and parathyroid-related peptide receptor, and rhodopsin (Spiegel and Weinstein, 2004) . The other type of activating polymorphisms increases ligand affinity or agonist efficacy in a way similar to the NPSR Ile 107 variant. Such mutations have been found in the Ca 2ϩ -sensing receptor and result in hypocalcemia and hypercalciuria (Pollak et al., 1994) .
Genetic variations in several GPCRs have also been associated with asthma susceptibility or effectiveness of asthma pharmacotherapy. A coding polymorphism in the cysteinylleukotriene receptor type 2 was found to reduce the affinity of the receptor to one of its major endogenous ligands, leukotriene D 4 . Because leukotriene D 4 is an important mediator of inflammatory responses in asthma, this polymorphism in cysteinyl-leukotriene receptor type 2 provides an asthmaprotective effect (Pillai et al., 2004) . Similarly, particular haplotypes in the promotor region of the prostanoid DP receptor (PTGDR) were found underrepresented in asthmatic patients. These polymorphisms lead to a reduced transcription of PTGDR mRNA and thus lower levels of receptor protein. Prostaglandin D2 (the endogenous ligand of PTGDR) is an important mediator of asthma, and PTGDR was found to be required for the development of airway sensitization in a mouse model of asthma. This might explain why reduced levels of PTGDR expression lead to an overall asthma-protective effect (Oguma et al., 2004) . Coding polymorphisms in the ␤ 2 -adrenoreceptor that influence receptor down-regula- tion in response to adrenergic agonists were found to be associated with the therapeutic benefit of ␤ 2 -agonists to treat symptoms of asthma (Israel et al., 2004) . Although ␤ 2 -adrenoreceptors are not causally involved in the pathophysiology of asthma, they are important therapeutic targets for acute and intermittent treatment of asthma symptoms. These examples illustrate the important contribution of specific GPCR genotypes for asthma susceptibility or therapy.
The observation of enhanced NPS-induced second messenger responses at NPSR Ile 107 could also have important consequences for brain function, because the predominant sites of NPSR expression are found in the central nervous system (Xu et al., 2004) . It might be possible that the Ile 107 isoform of NPSR is associated with changes in behavior or neuronal processing. In summary, we provide evidence that a naturally occurring polymorphism in the NPS receptor is producing a gain-of-function, resulting in enhanced second messenger signaling. Future research will have to demonstrate whether this polymorphism has functional significance in asthma or other physiological processes involving NPS signaling.
